Dss expands nutraceutical product lines through impact biomedical's investment in nano nutraceutical contract manufacturer nano9

Rochester, n.y., jan. 19, 2021 (globe newswire) -- document security systems, inc. (“dss” or the “company”) (nyse american: dss), a multinational company operating businesses focusing on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets, today announced its wholly owned subsidiary impact biomedical, inc. (“impact biomedical”) entered into an investment and distribution agreement with nano9 labs, llc (“nano9”), an r&d and contract manufacturing company specializing in the development of nano-sized nutraceutical products and ingredients.
DSS Ratings Summary
DSS Quant Ranking